Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sibutramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 known ✓ | Q01959 | 15/20 | 0.79 |
| ▸ | SLC6A4 known ✓ | P31645 | 14/20 | 0.79 |
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.79 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.79 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.79 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.79 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.79 |
| ▸ | HTR2A | P28223 | 1/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.79 |
| ▸ | HTR2B | P41595 | 1/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.77 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sibutramine SCHEMBL3705071 | 1.00 | SLC6A3 (0.79) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3707037 | 1.00 | SLC6A3 (0.79) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL4804258 | 0.91 | SLC6A3 (0.85) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL4804264 | 0.89 | SLC6A3 (0.81) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL27434458 | 0.89 | SLC6A3 (0.85) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL2672138 | 0.89 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL16312 | 0.89 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL2955 | 0.89 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL3707643 | 0.89 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A | |
| Sibutramine SCHEMBL7189499 | 0.87 | CYP3A4 (1.00) | SLC6A3SLC6A4SLC6A2CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010082216-A2 | NOVEL SALTS OF SIBUTRAMINE AND THEIR CRYSTAL FORMS | MATRIX LABORATORIES LTD (IN) | 2010-07-22 | — | — | WO | claimed |
| US-12485088-B2 | Rapidly-orodispersible tablets having an interior cavity | Aprecia Pharmaceuticals LLC (US) | 2025-12-02 | — | — | US | disclosed |
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | Triastek, Inc. (CN) | 2025-06-10 | — | — | US | disclosed |
| EP-4512394-A2 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240408023-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2024-12-12 | — | — | US | disclosed |
| EP-4171518-B1 | RAPIDLY-ORODISPERSIBLE TABLETS HAVING AN INTERIOR CAVITY | Aprecia Pharmaceuticals LLC (US) | 2024-12-11 | — | — | EP | disclosed |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | Triastek, Inc. (CN) | 2024-10-17 | — | — | US | disclosed |
| EP-3302442-B1 | DOSAGE FORMS AND USE THEREOF | TRIASTEK INC (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-12102721-B2 | Dosage forms of controlled release at specific gastrointestinal sites | Triastek, Inc. (CN) | 2024-10-01 | — | — | US | disclosed |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | Triastek, Inc. (CN) | 2024-07-23 | — | — | US | disclosed |
| WO-2018137686-A9 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2018-12-27 | — | — | WO | disclosed |
| US-10143626-B2 | Controlled release dosage form | Triastek, Inc. (CN) | 2018-12-04 | — | — | US | disclosed |
| US-20180311167-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2018-11-01 | — | — | US | disclosed |
| WO-2018137686-A1 | DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES | Triastek, Inc. (CN) | 2018-08-02 | — | — | WO | disclosed |
| US-20180116911-A1 | CONTROLLED RELEASE DOSAGE FORM | Triastek, Inc. (CN) | 2018-05-03 | — | — | US | disclosed |
| EP-3302442-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2018-04-11 | — | — | EP | disclosed |
| WO-2017193099-A1 | CONTROLLED RELEASE DOSAGE FORM | LI XIAOLING (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2016192680-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | WO | disclosed |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | Triastek, Inc. (CN) | 2016-12-08 | — | — | US | disclosed |
| WO-2010082216-A2 | NOVEL SALTS OF SIBUTRAMINE AND THEIR CRYSTAL FORMS | MATRIX LABORATORIES LTD (IN) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12324856-B2 | Oral drug dosage form comprising drug in the form of nanoparticles | CYP2D6, CYP3A5, CYP3A7 | SLC6A3 273/4885SLC6A4 268/4885SLC6A2 210/4885 |
| US-20160354315-A1 | DOSAGE FORMS AND USE THEREOF | CYP2D6, CYP3A7, CYP3A5 | SLC6A3 334/4885SLC6A4 209/4885SLC6A2 217/4885 |
| US-20240342094-A1 | COMPARTMENTED PHARMACEUTICAL DOSAGE FORMS | CYP2D6, CYP3A5, CYP2F1 | SLC6A3 595/4885SLC6A4 393/4885SLC6A2 297/4885 |
| US-12042562-B2 | 3D printing methods for compartmented pharmaceutical dosage forms | CYP3A43, HTR3D, CYP3A7 | SLC6A3 279/4885SLC6A4 205/4885SLC6A2 481/4885 |
| US-20180311167-A1 | DOSAGE FORMS AND USE THEREOF | CYP2D6, CYP3A7, CYP3A5 | SLC6A3 334/4885SLC6A4 209/4885SLC6A2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.